Cushman & Wakefield has announced the sale of a state-of-the-art pharmaceutical manufacturing facility located at 21 Tuas South Avenue 6, Singapore, with an indicative price of S$90m. The property spans approximately 935,341 square feet and includes a Gross Floor Area (GFA) of 397,387 square feet, with potential for further development.
The facility, situated in the heart of Tuas Biomedical Park, benefits from a 32-year remaining lease, a significant advantage over typical industrial leases in the area. The site also offers approximately 535,000 square feet of untapped GFA, supported by a greenfield land parcel ready for expansion. Its proximity to the upcoming Tuas Mega Port enhances its appeal for global distribution, particularly for temperature-sensitive pharmaceutical products.
Singapore’s reputation as a leading biomedical sciences hub in Asia makes it an attractive location for pharmaceutical and biotechnology companies. The city-state’s robust talent pool, advanced manufacturing capabilities, and dynamic research ecosystem continue to draw global investment. Total fixed asset investments in the biomedical manufacturing sector have nearly doubled year-on-year, reaching S$4.4b in 2025.
Brenda Ong, Executive Director of Logistics & Industrial at Cushman & Wakefield, highlighted the facility’s strategic location and expansion potential, stating, “This presents a rare opportunity for occupiers to acquire a plug-and-play facility with top-tier specifications, strategically located within Tuas Biomedical Park and in close proximity to the future Tuas Mega Port.”
The property is available for sale via private treaty. Interested parties are encouraged to contact Cushman & Wakefield Singapore’s Logistics and Industrial Services Team for further enquiries or to schedule a viewing.
